Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 3, 2020
- Accepted November 2, 2020
- First Published January 25, 2021.
Article Versions
- Previous version (January 25, 2021 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Rafid Mustafa, MD,
- Theodore J. Passe, MD,
- Alfonso S. Lopez-Chiriboga, MD,
- Brian G. Weinshenker, MD,
- Karl N. Krecke, MD,
- Nicholas L. Zalewski, MD,
- Felix E. Diehn, MD,
- Elia Sechi, MD,
- Jay Mandrekar, PhD,
- Timothy J. Kaufmann, MD,
- Padraig P. Morris, MD,
- Sean J. Pittock, MD,
- Michel Toledano, MD,
- Giuseppe Lanzino, MD,
- Allen J. Aksamit, MD,
- Neeraj Kumar, MD,
- Claudia F. Lucchinetti, MD and
- Eoin P. Flanagan, MB, BCh
- Rafid Mustafa, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Theodore J. Passe, MD,
NONE
NONE
Honoraria of $2,000 as invited speaker at the Neurology Resident Scholars Program paid by Creative Educational Concepts in September of 2020.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am a neuroradiologist at the Mayo Clinic in Rochester MN. Potentially an increase in spine MRI's with contrast would increase revenue to the clinic although I would not personally benefit directly as a salaried employee. This would be a very small part of our practice.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alfonso S. Lopez-Chiriboga, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Brian G. Weinshenker, MD,
NONE
NONE
1. Roche, honoraria for participation in symposia regarding neuromyelitis optica, World Congress of Neurology 2019
1. Canadian Journal of Neurological Sciences, editorial board member, 2006-present; no compensation 2. Turkish Journal of Neurology, editorial board member, 2005-present; no compensation
1) NMO-IgG for diagnosis of neuromyelitis optica; application 20050112116; patent issued and technology licensed to R.S.R. Ltd.,Oxford University,MVZ Labor PD Dr. Volkmann und Kollegen GbR, Hospices Civil de Lyon
NONE
NONE
1. Chugai: consulting regarding interpretation of neuromyelitis optica clinical trial 2. Mitsubishi Tanabe: consulting regarding design of neuromyelitis optica clinical trial
NONE
(1)VielaBio Pharmaceuticals, Adjudication Committee Member (2)Alexion Pharmaceuticals, Adjudication Committee Member
NONE
NONE
NONE
NONE
Guthy Jackson Charitable Foundation, sponsor of research in NMO, 10/2008-08/2017
NONE
NONE
NMO-IgG for diagnosis of neuromyelitis optica; patent issued and technology licensed to R.S.R. Ltd., Oxford University, MVZ Labor PD Dr. Volkmann und Kollegen GbR and Hospices Civil de Lyon
NONE
NONE
NONE
- Karl N. Krecke, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nicholas L. Zalewski, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Felix E. Diehn, MD,
NONE
NONE
(1) Non profit: ABR (American Board of Radiology)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elia Sechi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jay Mandrekar, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Timothy J. Kaufmann, MD,
NONE
NONE
NONE
American Journal of Neuroradiology Editorial Board member Neuro-Oncology Editorial Board member No compensation.
NONE
NONE
NONE
I have received honoraria as a consultant for SpineThera, a commercial entity unrelated to the current study.
NONE
NONE
NONE
NONE
Overcoming Therapy Resistance in Glioblastoma in: Mayo SPORE in Brain Cancer. Funded by National Cancer Institute. (P50 CA 108961) 09/2011 - 08/2016
NONE
NONE
Stock options in SpineThera
NONE
NONE
NONE
NONE
NONE
- Padraig P. Morris, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sean J. Pittock, MD,
Alexion Pharmaceutical Advisory Board Medimmune/Viele Bio Advisory Board UCB pharmaceuticals Astellas
NONE
NONE
NONE
Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) - Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, and a patent Patent# 9,891,219B2 (Application#12-573942) - Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued. Dr Pittock has a patent pending for GFAP, Septin-5, Kelch11 and MAP1B autoantibodies as biomarkers of neurological autoimmunity.
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
No activity to report. I am a salaried employee of Mayo Clinic and salary is fixed specialty dependent and not impacted by test volume or laboratory income.
NONE
Dr Pittock has received research funding from Grifols, Medimmune/Viela Bio, Alexion and AEA (Autoimmune Encephalitis Associations).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michel Toledano, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giuseppe Lanzino, MD,
Superior Medical Editing (Commercial for profit)
NONE
NONE
Journal of Neurosurgery, Editorial Board Member 2007-2013 Neurocritical Care, editorial Board Member 2009 Stroke, Section editor for Neurosurgery 2009-present
NONE
Cavernous Malformations of the Brain and Spinal Cord (Thieme,2008)
NONE
Superior Medical Editing Stock/Stock Options, Medical Equipment & Materials: Marblehead OneOme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Allen J. Aksamit, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
American Academy of Neurology
NONE
NONE
NONE
NONE
NONE
NONE
- Neeraj Kumar, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claudia F. Lucchinetti, MD and
(1)Member NIH/NINDS CNBT Study Section (2)Board of Trustee Member, Mayo Clinic (3)Board of Governor; Member, Mayo Clinic (4)Board of Directors, American Neurological Association (5)Director, American Neurological Association (ANA) Board of Directors
NONE
NONE
Brain Pathology, Guest Editor, NMO Symposium 2014
(1) patent re: aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica
(1)Blue Books of Neurology: Multiple Sclerosis 3 (Saunders Elsevier, 2010)
NONE
Biogen Idec, travel reimbursement only
NONE
NONE
NONE
(1)Amendment 3: A Synchrotron X-ray Fluorescence Based Approach to Examine the Role of Metals in Multiple Sclerosis Tissues. Biogen Idec. 2)Tissue Pathogenesis of Progression in Multiple Sclerosis. Mayo Clinic Development
(1) The role of microglia in neuromyelitis optica. NIH R01NS 110949-1. Role: Co-Investigator. 09/01/2019- 08/31/2024 (2)Diagnosis of indeterminate brain lesions using MRI- based machine learning and polygenic risk models. National Institute of Neurological Disorders and Stroke NS 113803. Role: Co-Investigator. 09/01/2019-08/31/2024 (3)Myelin oligodendrocyte glycoprotein antibody disease: incidence, prevalence, outcome prediction and immunopathology. National Institute of Neurological Disorders and Stroke R01NS 113828-1. Role: Co- Investigator. 09/01/2019-08/31/2024
NONE
(1) National Multiple Sclerosis Society: 07/01/2016 - 06/30/2021 (2)FTIR and XRF Microscopy of MS Lesions. Kingsland Foundation. 07/01/2016-06/30/2021
NONE
NONE
(1) aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica;
NONE
NONE
NONE
- Eoin P. Flanagan, MB, BCh
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am currently a site primary investigator in a randomized clinical trial on Medi551 in neuromyelitis optica spectrum disorder run by Medimmune. I receive compensation for time related to that activity.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Department of Neurology (RM, BGW, NLZ, ES, SJP, MT, AJA, NK, CFL, EPF), Department of Radiology (TJP, KNK, FED, TJK, PPM), Department of Biostatistics (JM), Department of Laboratory Medicine and Pathology (SJP, EPF), and Department of Neurologic Surgery (GL), Mayo Clinic College of Medicine & Science, Rochester, MN; and Department of Neurology, Mayo Clinic College of Medicine & Science (ASL-C), Jacksonville, FL.
- Correspondence
Dr. Flanagan flanagan.eoin{at}mayo.edu
Article usage
Cited By...
The Nerve!: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.